Key facts
- This page summarizes Giulia C. Kennedy's Form 4 filing for VERACYTE, INC. (VCYT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Dec 2022, 16:18.
Giulia C. Kennedy - 06 Dec 2022 Form 4 Insider Report for VERACYTE, INC. (VCYT)
- Reporting relationship
- Chief Scientific & Med Officer
- Issuer ticker
- VCYT
- Reported as of
- 06 Dec 2022
- Net transaction value
- -$27,652
- SEC form
- 4
- Accepted by SEC
- 08 Dec 2022, 16:18:49 UTC
- Prior SEC filing
- 06 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Wygant as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Giulia C. Kennedy filed Form 4 for VERACYTE, INC. (VCYT) on 08 Dec 2022.
Change
- Previous filing in this sequence was filed on 06 Dec 2022.
- Current net transaction value: -$27,652.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VCYT
transaction
Common Stock
Sale
- Transaction value
- $27,652
- Shares
- -1,023
- Change %
- -1.5%
- Price
- $27.03
- Shares after
- 65,970
- Date
- 06 Dec 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 14, 2022.